EP09: Uniting Science and Life: Obstetric APS and the Path to Healthier Pregnancies

At Werfen, our mission to Powering Patient Care includes advancing global understanding of thrombosis to improve health outcomes.

In honor of Antiphospholipid Syndrome Awareness Month, this issue focuses on Obstetric APS (OAPS), an APS variant affecting pregnancy at various stages and increasingly recognized as separate from its thrombotic counterpart.

Uniting Science and Life: Obstetric APS and the Path to Healthier Pregnancies

At Werfen, our mission to Powering Patient Care includes advancing global understanding of thrombosis to improve health outcomes.

In honor of Antiphospholipid Syndrome Awareness Month, this issue focuses on Obstetric APS (OAPS), an APS variant affecting pregnancy at various stages and increasingly recognized as separate from its thrombotic counterpart.

Epidemiology

Antiphospholipid Syndrome is a rare disease, more frequently diagnosed in women than in men. In the United States, the estimated annual prevalence of OAPS is around 4 cases per 100,000 individuals, with rates rising to 13 per 100,000 among women aged 30 to 39. If left untreated, fetal loss may occur in 30-80% of the pregnancies.

Clinical Presentation

OAPS is primarily characterized by recurrent early miscarriages and late obstetric complications derived from placental insufficiency and preeclampsia. Additional manifestations may include thrombosis, intrauterine growth restriction, placental abruption, and symptoms like livedo reticularis or thrombocytopenia.

Diagnosis

Beyond the established clinical criteria for the diagnosis of thrombotic APS, OAPS includes pregnancy morbidities, such as:

• Recurrent early miscarriages (3 or more unexplained spontaneous abortions before 10th week of gestation)
• Unexplained fetal deaths (at least 1 after 10 weeks of gestation)
• Preterm Deliveries (at least 1 before 34 weeks of gestation).

Laboratory tests must show persistent positivity for antiphospholipid antibodies (aPLs)—LA, aCL, and aβ2GPI—on two or more occasions at least 12 weeks apart.

Pathophysiology

APS current accepted pathogenesis follows a "two-hit" model, where aPLs first cause endothelial injury and then lead to thrombosis. In the case of OAPS, these antibodies trigger a pro-inflammatory response in the vascular walls of both fetal (trophoblastic) and maternal (decidual and uterine) tissues, rich in β2GPI. This cascade promotes thrombosis, impairs trophoblast function, disrupts placental development, and contributes to adverse pregnancy outcomes.

Prevention and Treatment

Low-dose aspirin and LMWH are standard for preventing thrombosis and reducing miscarriage rates, typically continued for 6–12 weeks postpartum. Therapeutic dosing is recommended in case of prior thrombosis.

In refractory situations, therapies like hydroxychloroquine, intravenous immunoglobulin (IVIG), or plasmapheresis may be considered to enhance effectiveness. Emerging options also include TNF-alpha inhibitors and complement inhibitors. 

Moving Toward Personalized Care

With appropriate management, many women with OAPS can now achieve healthy pregnancies. Preconception evaluation at specialized Multidisciplinary Care Centers allows for individualized risk profiling and care. Key strategies include patient stratification including non-criteria antibody testing, patient education, fetal monitoring, and delivery planning—each essential to minimizing maternal complications and supporting healthy neurodevelopmental outcomes for the baby.

Conclusions and Outlook

Obstetric APS represents a significant yet often underrecognized cause of pregnancy complications. As awareness grows and diagnostic and therapeutic tools evolve, personalized care is more achievable than ever. Through early identification, multidisciplinary collaboration, and tailored interventions, we can now improve maternal and fetal outcomes-empowering women with OAPS to pursue healthier pregnancies.